| Factor Information | |
|---|---|
| Data ID | 81 |
| Factor | Days on milrinone |
| Description | Compared with the SIMV-PRVC+PS group, the NAVA group had a statistically significant shorter median duration of days on dopamine and milrinone . |
| Biomarker | NA |
| Classification | A12 (clinical factor - treatment) |
| Association | |
|---|---|
| Application | diagnosis |
| Objective | To compare the median duration of days on dopamine , milrinone, midazolam and fentanyl between the NAVA and the SIMV-PRVC+PS group. |
| p Value | 0.0002 |
| Conclusion | The NAVA group demonstrated a shorter median duration of days on dopamine , milrinone, midazolam and fentanyl compared with the SIMV-PRVC+PS group. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 412 |
| CHD Type | isolated CHD |
| CHD Subtype | ALCAPA/HAA/AS/AVC/DORV/EA/HLHS/PA/Shone's Complex/TAPVR/TGV/TOF/TA |
| Reference | |
|---|---|
| PMID | 31073487 |
| Year | 2019 |
| Title | Neurally Adjusted Ventilatory Assist Is Associated with Greater Initial Extubation Success in Postoperative Congenital Heart Disease Patients when Compared to Conventional Mechanical Ventilation. |
| Sample | ||
|---|---|---|
| Population | Infants | |
| Source | Data | |
| Region | Tulsa, United States | |
| Method | non-randomized pilot study | |
| Race | North America | |
| Disease History | N/A | |
| Treatment History | postoperative CHD patients who required cardiopulmonary bypass and conventional MV for a minimum of 96 hours postoperatively without the ability to be weaned clinically or by blood gas analysis. | |
| Group | NAVA group(Treatment) | SIMV-PRVC+PS group(Control) |
| Number | 35 | 40 |
| Age | 1 month (Median) | 2 month (Median) |
| Gender (Male: Female) | 19:16 | 22:18 |
| Marker Level | intervention Median:9.0(5.0) | intervention Median:12.0(8.0) |
